4.6 Article

Pharmacological treatment of fragile X syndrome with GABAergic drugs in a knockout mouse model

Journal

BEHAVIOURAL BRAIN RESEARCH
Volume 229, Issue 1, Pages 244-249

Publisher

ELSEVIER
DOI: 10.1016/j.bbr.2012.01.031

Keywords

Fragile X syndrome; GABA(A) receptor; Neuroactive steroids; Ganaxolone; Mouse behaviour; Audiogenic seizures

Funding

  1. Belgian National Fund for Scientific Research - Flanders (FWO)
  2. Fragile X Research Foundation (FRAXA)
  3. Institute for the Promotion of Innovations through Science and Technology in Flanders (IWT Vlaanderen)
  4. Fondation Jerome Lejeune
  5. Interuniversity Poles of Attraction (IAP Network) of the Belgian Federal Science Policy Office [P6/43]
  6. Flemish Government

Ask authors/readers for more resources

Molecular and electrophysiological studies have provided evidence for a general downregulation of the GABAergic system in the Fmr1 knockout mouse. GABA(A) receptors are the main inhibitory receptors in the brain and the GABA(A) receptor was proposed as a novel target for treatment of the fragile X syndrome, the most frequent form of intellectual disability. This study examined the functionality of the GABA(A) receptor in rotarod and elevated plus maze tests with fragile X mice treated with GABA(A) receptor agonists, the benzodiazepine diazepam and the neuroactive steroid alphaxalone. In addition, the effect of GABA(A) receptor activation on the audiogenic seizure activity was determined. We proved that the GABA(A) receptor is still sensitive to GABAergic drugs as the sedative effect of diazepam resulted in a decreased latency time on the rotarod and alphaxalone had a clear anxiolytic effect in the elevated plus maze, decreasing the frequency of entries, the total time spent and the path length in the closed arms. We also observed that treatment with ganaxolone could rescue audiogenic seizures in Fmr1 knockout mice. These findings support the hypothesis that the GABA(A) receptor is a potential therapeutic target for fragile X syndrome. (C) 2012 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available